دورية أكاديمية
أعرض في EDS

FOXP1 and NDRG1 act differentially as downstream effectors of RAD9-mediated prostate cancer cell functions.

التفاصيل البيبلوغرافية
العنوان: FOXP1 and NDRG1 act differentially as downstream effectors of RAD9-mediated prostate cancer cell functions.
المؤلفون: Panigrahi SK; Center for Radiological Research, Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Broustas CG; Center for Radiological Research, Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Cuiper PQ; Center for Radiological Research, Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Virk RK; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA., Lieberman HB; Center for Radiological Research, Department of Radiation Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA. Electronic address: HBL1@columbia.edu.
المصدر: Cellular signalling [Cell Signal] 2021 Oct; Vol. 86, pp. 110091. Date of Electronic Publication: 2021 Jul 21.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Elsevier Science Ltd
Original Publication: Oxford ; New York : Pergamon Press, 1988-
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic* , Prostatic Neoplasms*/pathology, Cell Cycle Proteins/*metabolism , Intracellular Signaling Peptides and Proteins/*metabolism, Cell Line, Tumor ; Cell Proliferation ; Forkhead Transcription Factors/genetics ; Forkhead Transcription Factors/metabolism ; Humans ; Male ; Repressor Proteins/metabolism ; Transcription Factors/metabolism
مستخلص: Metastatic progression is the key feature of prostate cancer primarily responsible for mortality caused by this disease. RAD9 is an oncogene for prostate cancer, and the encoded protein enhances metastasis-related phenotypes. RAD9 is a transcription factor with a limited set of regulated target genes, but the complete list of downstream genes critical for prostate carcinogenesis is unknown. We used microarray gene expression profiling and chromatin immunoprecipitation in parallel to identify genes transcriptionally controlled by RAD9 that contribute to this cancer. We found expression of 44 genes altered in human prostate cancer DU145 cells when RAD9 is knocked down by siRNA, and all of them bind RAD9 at their genomic location. FOXP1 and NDRG1 were down regulated when RAD9 expression was reduced, and we evaluated them further. We demonstrate that reduced RAD9, FOXP1 or NDGR1 expression decreases cell proliferation, rapid migration, anchorage-independent growth, anoikis resistance, and aerobic glycolysis. Ectopic expression of FOXP1 or NDRG1 partially restored aerobic glycolysis to prostate cancer cells with reduced RAD9 abundance, but only FOXP1 significantly complemented the other deficiencies. We thus show, for the first time, that RAD9 regulates FOXP1 and NDRG1 expression, and they function differently as downstream effectors for RAD9-mediated prostate cancer cell activities.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
References: PLoS Genet. 2013;9(8):e1003726. (PMID: 23966881)
Mol Cell Biol. 2006 Mar;26(5):1850-64. (PMID: 16479004)
Science. 2014 Jan 3;343(6166):84-87. (PMID: 24336571)
Neoplasia. 2007 Dec;9(12):1152-9. (PMID: 18084622)
Oncogene. 2004 Jul 22;23(33):5675-81. (PMID: 15184886)
J Biol Chem. 2002 Jul 19;277(29):26699-707. (PMID: 12011055)
Apoptosis. 2017 Sep;22(9):1116-1137. (PMID: 28653224)
Cancer Res. 2008 Mar 1;68(5):1267-74. (PMID: 18316588)
DNA Repair (Amst). 2013 Apr 1;12(4):284-92. (PMID: 23433811)
Nat Rev Urol. 2020 Apr;17(4):214-231. (PMID: 32112053)
Mol Carcinog. 2008 Jun;47(6):458-65. (PMID: 18058807)
Cancer Res. 2003 Apr 15;63(8):1731-6. (PMID: 12702552)
Cancer Res. 2004 Jul 1;64(13):4585-92. (PMID: 15231670)
Blood. 2011 Jun 9;117(23):6227-36. (PMID: 21460242)
Mol Oncol. 2017 Jun;11(6):655-669. (PMID: 28371345)
Cell. 2007 Sep 21;130(6):1160. (PMID: 17889656)
Nucleic Acids Res. 2015 May 19;43(9):4531-46. (PMID: 25873625)
Int J Mol Sci. 2016 Sep 08;17(9):. (PMID: 27618020)
J Cell Sci. 2014 Jul 15;127(Pt 14):3116-30. (PMID: 24829151)
BMC Mol Biol. 2007 May 21;8:37. (PMID: 17511890)
Mol Biol Rep. 2013 May;40(5):3723-9. (PMID: 23526365)
Oncogene. 1995 Aug 17;11(4):723-33. (PMID: 7651736)
Front Physiol. 2017 Feb 21;8:97. (PMID: 28270771)
Radiat Res. 2017 Apr;187(4):424-432. (PMID: 28140789)
Carcinogenesis. 2019 Mar 12;40(1):164-172. (PMID: 30295739)
Genes Dev. 2002 Jan 15;16(2):198-208. (PMID: 11799063)
Carcinogenesis. 2014 Jul;35(7):1481-90. (PMID: 24403312)
Biochem Biophys Res Commun. 2018 Oct 28;505(2):554-560. (PMID: 30274777)
Nucleic Acids Res. 2008 Nov;36(20):6406-17. (PMID: 18842633)
Nat Commun. 2017 Oct 20;8(1):1081. (PMID: 29057879)
J Clin Pathol. 2012 Jun;65(6):528-33. (PMID: 22422806)
J Biol Chem. 2004 Nov 19;279(47):48930-40. (PMID: 15377670)
PLoS One. 2013 Dec 27;8(12):e84295. (PMID: 24386364)
J Biol Chem. 2009 May 29;284(22):15158-72. (PMID: 19329425)
Mol Cell Biol. 2004 Aug;24(16):7235-48. (PMID: 15282322)
Oncogene. 2020 Mar;39(12):2467-2477. (PMID: 31980741)
J Proteome Res. 2015 Dec 4;14(12):5263-72. (PMID: 26506913)
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8864-9. (PMID: 15184659)
Oncotarget. 2016 Jan 19;7(3):3506-19. (PMID: 26654944)
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8591-5. (PMID: 7567980)
J Biol Chem. 2012 Nov 30;287(49):41324-33. (PMID: 23066031)
Mol Cancer. 2017 Feb 1;16(1):29. (PMID: 28148257)
Nat Cell Biol. 2000 Jan;2(1):1-6. (PMID: 10620799)
Oncotarget. 2017 Jun 17;8(57):97693-97700. (PMID: 29228644)
Cancer Metab. 2013 Mar 07;1(1):10. (PMID: 24280167)
Oncotarget. 2015 Apr 20;6(11):8851-74. (PMID: 25860930)
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14373-8. (PMID: 19597154)
BMC Genet. 2004 Sep 02;5:27. (PMID: 15341671)
Mol Cell Biol. 1999 Feb;19(2):1279-88. (PMID: 9891062)
Biochem Biophys Res Commun. 2008 Sep 19;374(2):388-93. (PMID: 18640093)
Science. 1956 Feb 24;123(3191):309-14. (PMID: 13298683)
معلومات مُعتمدة: R01 CA130536 United States CA NCI NIH HHS; UL1 TR001873 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: FOXP1; NDRG1; Prostate cancer; RAD9
المشرفين على المادة: 0 (Cell Cycle Proteins)
0 (FOXP1 protein, human)
0 (Forkhead Transcription Factors)
0 (Intracellular Signaling Peptides and Proteins)
0 (N-myc downstream-regulated gene 1 protein)
0 (Repressor Proteins)
0 (Transcription Factors)
تواريخ الأحداث: Date Created: 20210723 Date Completed: 20220331 Latest Revision: 20221003
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8403642
DOI: 10.1016/j.cellsig.2021.110091
PMID: 34298089
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-3913
DOI:10.1016/j.cellsig.2021.110091